This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kirmizis, A. Articles by Farnham, P. J. Search for Related Content PubMed PubMed Citation Articles by Kirmizis, A. Articles by Farnham, P. J.

McArdle Laboratory for Cancer Research, University of Wisconsin Medical School, Madison, Wisconsin 53706

2 To whom requests for reprints should be addressed, at McArdle Laboratory for Cancer Research, University of Wisconsin, 1400 University Avenue, Madison, WI 53706. Phone: (608) 262-2071; Fax: (608) 262-2824; E-mail: farnham{at}oncology.wisc.edu

We have previously identified SU(Z)12 as an E2F target gene. Because many E2F target genes encode proteins that are critical for the control of cell proliferation, we have further characterized the regulation and expression of SU(Z)12. To understand the molecular mechanisms responsible for expression of SU(Z)12 mRNA, we have analyzed the promoter region. We found that the SU(Z)12 gene is controlled by dual promoters, one of which functions bidirectionally. In addition to the E2F binding site, we have identified two binding sites for T cell factor (TCF)/ß-catenin complexes. Using gel mobility shift assays, we demonstrated that both TCF sites can be bound by TCF4. TCF/ß-catenin complexes have been shown to be a critical regulator of gene expression in tumors of the colon, breast, and liver. Accordingly, we have used chromatin immunoprecipitation assays to confirm that TCF4/ß-catenin complexes are bound to the SU(Z)12 promoter in colon cancer cells but not in HeLa cells. We next adapted the chromatin immunoprecipitation assay for use with primary colon tumor samples, and, using matched pairs of normal and tumor tissue obtained from several different colon cancer patients, we demonstrate that levels of ß-catenin bound to the SU(Z)12 promoter are increased in colon tumors. Finally, we show that the SU(Z)12 mRNA is up-regulated in a number of different human tumors, including tumors of the colon, breast, and liver. Recent studies have found that SU(Z)12 is a component of the Drosophila ESC-E(Z) and the human EED-EZH2 Polycomb chromatin remodeling complexes. Therefore, we suggest that SU(Z)12, which may modulate the tumor phenotype by changing gene expression profiles, may be a logical target for the design of a new antitumor agent

This article has been cited by other articles:

				S. Wohrle, B. Wallmen, and A. Hecht Differential Control of Wnt Target Genes Involves Epigenetic Mechanisms and Selective Promoter Occupancy by T-Cell Factors Mol. Cell. Biol., December 1, 2007; 27(23): 8164 - 8177. [Abstract] [Full Text] [PDF]

				V. K. Rajasekhar and M. Begemann Concise Review: Roles of Polycomb Group Proteins in Development and Disease: A Stem Cell Perspective Stem Cells, October 1, 2007; 25(10): 2498 - 2510. [Abstract] [Full Text] [PDF]

				J. Tan, X. Yang, L. Zhuang, X. Jiang, W. Chen, P. L. Lee, R.K. M. Karuturi, P. B. O. Tan, E. T. Liu, and Q. Yu Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells Genes & Dev., May 1, 2007; 21(9): 1050 - 1063. [Abstract] [Full Text] [PDF]

				A. H. Ting, K. M. McGarvey, and S. B. Baylin The cancer epigenome--components and functional correlates Genes & Dev., December 1, 2006; 20(23): 3215 - 3231. [Abstract] [Full Text] [PDF]

				L. Elnitski, V. X. Jin, P. J. Farnham, and S. J.M. Jones Locating mammalian transcription factor binding sites: A survey of computational and experimental techniques Genome Res., December 1, 2006; 16(12): 1455 - 1464. [Abstract] [Full Text] [PDF]

				P. A. Reynolds, M. Sigaroudinia, G. Zardo, M. B. Wilson, G. M. Benton, C. J. Miller, C. Hong, J. Fridlyand, J. F. Costello, and T. D. Tlsty Tumor Suppressor p16INK4A Regulates Polycomb-mediated DNA Hypermethylation in Human Mammary Epithelial Cells J. Biol. Chem., August 25, 2006; 281(34): 24790 - 24802. [Abstract] [Full Text] [PDF]

				L.-B. Song, M.-S. Zeng, W.-T. Liao, L. Zhang, H.-Y. Mo, W.-L. Liu, J.-Y. Shao, Q.-L. Wu, M.-Z. Li, Y.-F. Xia, et al. Bmi-1 Is a Novel Molecular Marker of Nasopharyngeal Carcinoma Progression and Immortalizes Primary Human Nasopharyngeal Epithelial Cells. Cancer Res., June 15, 2006; 66(12): 6225 - 6232. [Abstract] [Full Text] [PDF]

				P. H. Abbosh, J. S. Montgomery, J. A. Starkey, M. Novotny, E. G. Zuhowski, M. J. Egorin, A. P. Moseman, A. Golas, K. M. Brannon, C. Balch, et al. Dominant-Negative Histone H3 Lysine 27 Mutant Derepresses Silenced Tumor Suppressor Genes and Reverses the Drug-Resistant Phenotype in Cancer Cells Cancer Res., June 1, 2006; 66(11): 5582 - 5591. [Abstract] [Full Text] [PDF]

				A. M. Holmes, K. A. Weedmark, and G. B. Gloor Mutations in the extra sex combs and Enhancer of Polycomb Genes Increase Homologous Recombination in Somatic Cells of Drosophila melanogaster Genetics, April 1, 2006; 172(4): 2367 - 2377. [Abstract] [Full Text] [PDF]

				K. Collett, G. E. Eide, J. Arnes, I. M. Stefansson, J. Eide, A. Braaten, T. Aas, A. P. Otte, and L. A. Akslen Expression of Enhancer of Zeste Homologue 2 Is Significantly Associated with Increased Tumor Cell Proliferation and Is a Marker of Aggressive Breast Cancer Clin. Cancer Res., February 15, 2006; 12(4): 1168 - 1174. [Abstract] [Full Text] [PDF]

				I. M. Bachmann, O. J. Halvorsen, K. Collett, I. M. Stefansson, O. Straume, S. A. Haukaas, H. B. Salvesen, A. P. Otte, and L. A. Akslen EZH2 Expression Is Associated With High Proliferation Rate and Aggressive Tumor Subgroups in Cutaneous Melanoma and Cancers of the Endometrium, Prostate, and Breast J. Clin. Oncol., January 10, 2006; 24(2): 268 - 273. [Abstract] [Full Text] [PDF]

				J. Chen, A. Wu, H. Sun, R. Drakas, C. Garofalo, S. Cascio, E. Surmacz, and R. Baserga Functional Significance of Type 1 Insulin-like Growth Factor-mediated Nuclear Translocation of the Insulin Receptor Substrate-1 and {beta}-Catenin J. Biol. Chem., August 19, 2005; 280(33): 29912 - 29920. [Abstract] [Full Text] [PDF]

				R. J. Gibbons Histone modifying and chromatin remodelling enzymes in cancer and dysplastic syndromes Hum. Mol. Genet., April 15, 2005; 14(suppl_1): R85 - R92. [Abstract] [Full Text] [PDF]

				A. Kuzmichev, R. Margueron, A. Vaquero, T. S. Preissner, M. Scher, A. Kirmizis, X. Ouyang, N. Brockdorff, C. Abate-Shen, P. Farnham, et al. Composition and histone substrates of polycomb repressive group complexes change during cellular differentiation PNAS, February 8, 2005; 102(6): 1859 - 1864. [Abstract] [Full Text] [PDF]

				A. Kirmizis and P. J. Farnham Genomic Approaches That Aid in the Identification of Transcription Factor Target Genes Experimental Biology and Medicine, September 1, 2004; 229(8): 705 - 721. [Abstract] [Full Text] [PDF]

				A. Kirmizis, S. M. Bartley, A. Kuzmichev, R. Margueron, D. Reinberg, R. Green, and P. J. Farnham Silencing of human polycomb target genes is associated with methylation of histone H3 Lys 27 Genes & Dev., July 1, 2004; 18(13): 1592 - 1605. [Abstract] [Full Text] [PDF]

				C. Muller-Tidow, B. Steffen, T. Cauvet, L. Tickenbrock, P. Ji, S. Diederichs, B. Sargin, G. Kohler, M. Stelljes, E. Puccetti, et al. Translocation Products in Acute Myeloid Leukemia Activate the Wnt Signaling Pathway in Hematopoietic Cells Mol. Cell. Biol., April 1, 2004; 24(7): 2890 - 2904. [Abstract] [Full Text] [PDF]

				M. J. Oberley, D. R. Inman, and P. J. Farnham E2F6 Negatively Regulates BRCA1 in Human Cancer Cells without Methylation of Histone H3 on Lysine 9 J. Biol. Chem., October 24, 2003; 278(43): 42466 - 42476. [Abstract] [Full Text] [PDF]